Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect - Companies and Markets adds new report

2008-09-27 17:25:03 - Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/Forecast-Insig ..

Introduction

Stimulated by evidence of disease slowing with Teva/Lundbeck´s Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson´s disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.

Scope

*This report gives a strategic analysis of the likely impact that recent events will

 

 

have on the future Parkinson´s disease market

*Includes Parkinson´s disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

*Provides a global market snapshot by including Parkinson´s disease-specific sales analysis for leading brands outside the seven major markets

*Key conclusions are supported by key opinion leader comment

Highlights

Datamonitor has upgraded its forecasts of Teva/Lundbeck´s Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson´s disease drug at this time.

GlaxoSmithKline´s Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim´s Mirapex (pramipexole).

Datamonitor has downgraded its sales forecasts of UCB´s Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB´s misfortune.

Reasons to Purchase

*Understand the impact of recent and anticipated events on the Parkinson´s disease market during the forecast period 2008 to 2017

*Quantify the current size of the seven major markets and the trends in the rest of the world

*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson´s disease-specific sales of key brands


www.companiesandmarkets.com/Summary-Market-Report/Forecast-Insig ..